centre antoine lacassagne nice protocoles et …...centre antoine lacassagne nice j.p. gerard...
TRANSCRIPT
1Amiens, 22 novembre 2014
Centre Antoine Lacassagne
Nice
J.P. GERARD
Radiothérapie et
cancer du rectum
Protocoles et Indications
2
DISCLOSURE
Ariane Medical SystemsTM (UK)
Contact Brachytherapy X Ray 50 kV
"Papillon 50"
J.P. GERARD
Medical Advisor
Philips
RT 50
20091971
PLAN
• les techniques de Radiothérapie (externe- curie)
• Traitements neo-adjuvants : Phase III (rationel)
• Les protocoles ( TNCD – thésaurus )
• Les Essais en cours (et à venir)
• 1970
Linear accelerator
X 10-18 MV
. 1995
Digital -Computer
RC 3D - IMRT
Contouring : GTV -
CTV and OAR
3D CT scan
simulation
CTV
GTV
OAR
6
Nice
Total dose
50 Gy
44 + 6
(boost)
T2 N0
Overview
Treatment
Plan
Isodose
Display
44 Gy
7
RT+
Loc Recurrence Green : pN0, Red : pN1
J Nijkamp, IJROBP 2010 Dutch TME below S2/S3
Treatment room
Positionning : laser
Image guided
Dynamic arc
1
2 3
- Multi leaf collimator (1)
- Conformal 3D RT (2)
- Intensity modulated RT (3)
(IMRT : concave)
IGRT : Image guided
Adaptive
Radiotherapy
Novalis
KV.KV - cone beam CT
TomoTherapy
Field Matching DRR vs kV image : Lateral Field
CyberknifeTomotherapy Linac
Vero Novalis – Gama Knife
radiotherapy machines
EDGE
V Mat
1313/2009 13/2009
"CAP 50“ French Standard 2012
RXTherapy 50Gy / 25fractions / 5 weeks
2Gy/fraction
field shrincking after 44 Gy
Capecitabine 1.600 mg/m2/day
(800 mg bid) (825)
on RXT days (not W.E.)
RT Dose/volume Effect - « small volume »
Marie Curie and Albert Einstein
Lac Leman, Suisse 1925
Radium
Discovery
Curietherapy
BRACHYtherapy
/2009 15
interstitial HDR
Brachytherapy Ir192
1
/2009 16
1
2
BRACHYTERAPY
1) Contact X Ray
Brachytherapy
X 50 Kv
CXBP 50
2) Endoluminal
HDR Brachy
Iridium 192
17
Contact x-ray 50 kv Papillon technique
Philips
CXB
50 Kv
1968
1971
cCR
30 Gy
2mn
30 Gy
/2009 18
CXB unique RT = high precision with eye guided
into Small Volume (5cm3) : HIGH DOSE / Fraction
30.Gy
2 min.
Transanal Endoscopic radiotherapy
19
T1
T3LEGRAND tm
KNEE - CHEST
CCR
Rectoscope
disposable
RECTOSCOPY + DRE in KNEE CHEST POSITION
« BIOPROBE »
Papillon50TM
Transanal Endoscopic
Contact X Ray
brachytherapy 50 kv
CXB
2009
Papillon 50 TM Transanal Endoscopic CXBAccurate Targeting . Ambulatory . Any age
1) Scope-Target 2) Fixation 3) Irradiation
/2009 23
Local excision (TEM) or
T2-3 Nxcombined CBX+EBRT
Watch / Wait
EBRTCBX 50kV +
24
uT3N0
Day 1
Day 21 7 years
1992
25
Mr W.
74 y
Oct. 2010
T2N0CXB
110 Gy
CAP 50
CCR
07/2014 :
Loc Cont
D1 : 35Gy
D28 : after 65Gy D35 : CCR
/2009 26/2009 26
Mr Boe 84 y Card. Ins.
ADK uT3 N0 3cm diam. low R.
March 2009 : CBX (100 Gy)
CAP 50 = Jan. 2014 : NED
1995
C
C
CC : Cure : 50%
C : Conservative
C : Cost effective
Radiotherapy
3 C
Relevance of Radiotherapy
« 3 C »
Cure : 50 % of patients treated with RXT
Conservative : eye, larynx, breast, rectum etc…
Cost – effective : France Health : 200 B €
Cancer : 20 B € - Radiotherapy : < 2 B €
RT many various –complex techniques
“Tailored treatment” - “sur mesure”
/2009/2009
SURGERY : main treatment Rectal Kc
• TME : sharp dissection/ visual control (R0, nerve)
• ISR Inter-sphinteric : bowel function ?
• LAPAROSCOPIC Surgery (« health capital »)
• Robotic surgery (17 M € ) ?
Anesthesiology- Intensive Care :
60 days post – op mortality < 2% +++
/2009/2009
TME SURGERY : APE
Extra-Levator A P E
APE :
T3 bad - T4
Distal rectum
R0 : CRM −
Waist
Courtesy
Ph Quirke
/2009/2009
- Surgery ("TME") main treatment.
Neo (adjuvant )treatment benefit ?
Evidence Based Medecine
ONLY RANDOMIZED TRIALS
/2009/2009
Neo (adjuvant) phase III – O verview
- NIH ( JAMA 1999) : Postop chemoRT Standard
- 2004 : German / Sweden: preop > post op
- 2006 : FFCD-EORTC : chemoRT > RT alone
- 2010 : ACCORD12 : RT dose 50 Gy > 45
- 2012 : STAR-NSABP- PETACC6 : no Conc. oxalipt.
- 2003 : Dutch + CRO7 : 5x5 useful with TME
/2009/2009
Benefit of neoadjuvant CRT : modest
• Local control : YES ….. « TME surgery »
• Survival : NO
• Toxicity : Post-op death , anesthes. Volume RT !
• Conservative treatment ?
- Bujko : Rad. Oncol. 2006;8:4.
- Gérard : Crit. Rev. Hem. Oncol. 2012,81:28
34/2009 3430/05/2009
Does rectal cancer shrinkage induced
by preoperative RT (chemo) increase
the likelihood of anterior resection ?
References
K. Bujko – Radioth Oncol 2006; 8:
4-12
Gerard - Crit Rev Hemat onco 2012
JP Gérard Crit Rev Onc. Hem. 2012 Jan;81(1):21-8
Sph
Spincter
Saving
36
SEOUL : Rectum T3-4 M0 Ph III – pre vs post CRT
Preop 107 Postop 113
LAR 80 % 72 % (NS)
ypT0 21 % 0 %
Loc. Rec. (4y) 4 % 6 %
DFS (3y) 77 % 73 %
Late Toxicity G3-4 8 % 3 %
Med Age : 55 - Distal R : 52 % "CAP 50"
Park – Cancer 2011 ;117:3703
37/2009 3730/05/2009
Does rectal cancer downsizing induced
by preoperative RT (chemo) increase
the likelihood of
Sphincter preservation anterior resection?
References
K. Bujko – Radioth Oncol 2006; 8: 4-12
Gerard - Crit Rev Hemat onco 2012 ;81:8
NO ! ! WHY ?
/200930/05/2009
Adenocarcinoma rectum : radioresistantRadiation Dose-Response Model (EQD 2)
A Appelt-Jakobsen Int J R OBP 2013 ; 85: 74
T3 rectal ADKypCR
Veijle : 222 ptsEBRT + Brachy Ir
D 50% = 92 Gy[79- 145 ] 95 % CI
39/2009 39
INTERVAL : LYON R 90-01 Phase III
(François; Gérard JCO 1999; 17: 2396)
Short2 (2w) Int (99) Long (6w) Int (102)
Yp CR 7% 14% (0.1)
Sphinter preserv. 69% 79% (NS)
" (<6 cm) 23% 41%
Post-op death 3% 4%
Loc. rec. (5 yrs) 13% 10%
Ov. Surv (5 yrs) 68% 66%
Cracow : 5x5 short vs long interv. 154 pts : pCR: 0% vs 10% no diff in SSS (2012)
4040
15 year follow-up
Overall survival :
48 %
NO Difference
pCR is a marker of
good prognosis not
a cause
2nd primary cancer
9%
Wang PMH : 13 weeks - Dutch: 11 weeks
Traitement conservateur - Essais
• GRECCAR 6 T3 T4 Phase III Endpoint : ypCR
délai 7 semaines
délai 12 semaines
End Point : ypCR
RRCT preop
42
Cumulative incidence local recurrence
Time in month
Cu
mu
lati
ve
in
cid
en
ce
RT
CT-RT
FFCD 9203 JCO 2006
60 120
Chemo-Radiotherapy 5-FU
43
ACCORD 12 – RT dose effectGérard et al. J Clin Oncol 2010, 28: 1638
Cap 45 (287) Capox 50 (287)
Toxicity G3-4 11 % 25 % <0.001
Ant Resect 74 % 76 %
Death 60 days 0.3 % 0.3 %
Dworak ypCR 13.9 % 19.2 % 0.09
No + few residual
cells
29 % 39 % 0.002
CRM + 1 mm 12 % 7 % 0.17
CRM + 2 mm 19 % 10 % 0.02
/2009/2009
SAFE Radiation Dose escalation : EVIDENCE
PHASE III Lyon R96-02
• T2-3 < 1/2 circumf 6 cm Anal Verge (distal rectum)
R
EBRT (39 Gy/4w)
Cont X Brachy (90 Gy/3) + EBRT
Gérard : J Clin Oncol 2004; 22 : 2404
• End Point : sphincter preservation : 40% 70 %
• 1996 – 2001 : 88 pts randomized
45
Lyon R96-02 - Results- EVIDENCE
CBX : median dose : 85 Gy/3F Median interval : 5 weeks
No chemotherapy - Operable Patients
EBRT (43) CXB+EBRT (45)
cCR 1 (2%) 11 (29 %) p<0.05
APE 24 (56%) 11 (24%)
Sph. Saving Tt 19 (44%) 34 (76%) p=0.004
RT alone (Org) 0 7 (cCR : 7)
Loc. Exc. (Pre) 0 3 (cCR : 2)22%
Gerard JCO 2004;22: 2404
46
Lyon R 96-02 - 10 years Fol.up
EBRT (43) CXB 90 Gy + EBRT (45)
cCR 2 % 29 % < 0.05
Sph. Sav. Sgy 44 % 76 % < 0.05
Organ preserv. 0 10 (3+7) < 0.05
10 y stomy free 29% 61% <
0.05
Loc. Rec. (10 y) 16 % 11 %
Ov. Surv. (10 y) 55 % 55 %Gérard : JCO 2004 ;22:2404 - Ortholan : IJROBP 2012 ; 83: e165
/200947/2009 47/2009/2009 47
Day 1
uT2N0
Day 70
pT0N0 14 years
1999
cCR
Lyon R96.2 – Phase III – 10 years : Good Evidence
Safe dose escalation with CXB 50 kV
- Increases 30% clinical complete response
- higher rate 30% sphincter preservation
May provide organ preservation
Surgeon may reappraise the strategy
No perirectal Lymph Node relapse
C. Ortholan – J.P. Gérard
Dis Colon Rectum 2006 ; 49 : 1-9
Clinial Complete Response cCR
The CLINICAL complete response hypothesis
Radioresistance
PR
« clinical complete response is defined :
- total disappearance of the tumor,
- normal supple mucosa and rectal wall
on digital and rectoscopic examination »
Int. J Rad Onc Biol Phys 1996 ;34:775-83
/2009/2009
Cancer du rectum
Radiothérapie
Indications
TNCD :Thésaurus National de Cancérologie Digestive
- Promoteur : SNFGE
- Groupe de travail
analyse littérature – rédaction
- Groupe de relecture
modification – correction – discussion
- Comité de pilotage : SNFGE – FFCD – GERCOR
FNCLCC – SFCO – SFRO
arbritage – validation (E. Dorval)
- www.tncd.org
53STRATEGIE
54
STRATEGIE
/2009/2009
Cancer du rectum
Radiothérapie :
Radiothérapie de Contact
Organ Preservation
-
56
Day 1
T1N0
CXB
Day 21
Day 7
8 years
/2009 57
Rectal cancer T1 N0 - Contact
• Local Excision FIRST ++
• CXB 50 Kv adjuvant
+ postop RXT
Selection +++ (path specimen)
endoscopic submucosal dissection ESD gastroenterologist
Full thickness trans anal Exc. TEM surgeon
Cortesy
P O Toole
No risk (< 5%) : surveillance
Risk in tumor bed only : CXB alone
Total Dose : 50 Gy / 3 Fr / 3 w
Risk in T + N ≥ 10% : CXB + EBRT± Chemo
CXB : 30 Gy/ 2 Fr + CAP 50
APE should be exceptional in pT1
Pathological report - Decision
Papillon50TM
intraluminal
Contact brachy X 50
kv
/2009 61
Day 1
Day 21
Adjuvant
Contact X B
50 Gy/3 fr. 3weeks
Applic: 3 cm
T1 N0Local Excision
Adverse Pathology
Acta Oncol
Jp Gérard et al
Nov 2014
Local excision + adjvuant CXB ± EBRT
Ref N° pt pTis pT1 pT2 Loc Cont OS 5 y
Lyon
1980-1995 43 4 34 5 93% 80%
Nice
2004-2012 20 2 15 3 96% 82%
Total 63 6 49 8 95% 84%
Gérard Gastroent. Cl. Biol. 2000;24:430 Gérard IJROBP 2006
NO isolated lymph node relapse
64
T2 T3 : Organ preservation Rectum
1- Papillon
CXB:
T1: 90% contrôle local
2- Habr Gama
Chimioradiothérapie
Watch and Wait
« Early T2 -3 »: 40% contrôle
/2009/2009
A. Habr Gama – R. Perez – Sao Paulo (1991-2011)
T2-3 N0-1 Rectal cancer (≤ 7 cm AV) : 183 pts
CRT : 50-54 Gy (1.8) + 5FU : delay 8 weeks (Med Fup : 5y)
- cCR : 49% 90/183
- Local recurrence : 31% (28/90) (17 E + 11 late)
- Salvage : 79% 22/28 (primary T)
- 5y DFS : 68%
- 5y loc control : 94%
- Dist Met : 14% (13/90)
- Organ preservation : 78% (70/90) 39% : 70/183
Habr Gama Int J rad Onc B Phys 2014;13:360
/2009/2009
GRECCAR II – T2T3 < 4 cm- Phase III 2007-12
195 Pts T2 -3 < 4cm N0-1 ≤ 8cm AV
CAP 50 : if T < 2 cm : R. TME vs L.E.
145 pts random : 71% responders < 2 cm
71 TME : 40% pCR - ypT1: 21%
74 LE : 26 « salvage » TME (ypT2-R1)
48 pts : organ preservation (38%)
ypT0-1 all pN0 - Loc Rec ??
Local Excision (fat) : always even cCR
Vendrely Rullier Rouanet IJROBP 2014;90 abst 34
Acta Oncol
Jp Gérard et al
Nov 2014
T2 T3 CXB + EBRT : 120 Pts - Results
Ref N° pt age T2 T 3 cCR Loc Rec Sp S 5 y
Lyon
1986-2001 80 73 52 28 94% 27% 72 %
Nice
2002-2012 40 81 22 18 95% 12% 70 %
Total 120 76 74 46 94% 20% 71 %
Gérard IJROBP 2002 ; 54: 142 - Gérard Acta Oncol Nov 2014
NO isolated lymph node relapse
Clatterbridge - Liverpool
The Papillon ClinicPr A. Sun Myint
Papillon Clinic
/2009
Clatterbridge – Liverpool – A. Sun Mynt combined nCRT +
CBX elderly patient
- 2006-2011 : 132 pts m. Age : 74
- T2 : 79 T3 : 53
- Cap 45 Gy + CBX 90 Gy/3F
- Median Fol-up : 3 years
- CCR : T2 : 84% T3 : 72%
- Loc. Rec. after cCR : 4% (4/107)
Neoadjuvant Treatment and cCR
cCR : 30-50% cCR : 60-85%
Escalating RT dose with endocavitary boost (XRB – HDR)
increases cCR by 30% with acceptable toxicity.
EBRT EBRT + boost endocavitary
T2 – T3 – CCR : ↑ 30% CRT + XRBHabr Gama Mass, Beets Gérard Sun Myint
CRT alone
30-50%
CRT + contact XRB boost
60-85%cCR :
Thésaurus TNCD
- Consensus au « temps t »
- Evolutif (internet / marbre)
- Aide à la décision pratique en RCP
- L’avenir : Les essais cliniques
snfge.org TNCD – rectum 2013
7474
France – Phase III – 2014 : SURVIE
• Prodige 23 : T3-4 M0 (≤ 75 y) (T Conroy)
CAP50 – 6w – TME
Folfirinox (4 cycles/2 months)
CAP50 – 6 w – TME
End point : 3 year DFS 75% vs 85% 460 pts
R
75
RAPIDO (Sweden)
• Inclusion : MRI : "T3 c-d" – T4 (N2 ?) CRM+
CRT (8w) TME – Xelox (4 months)
5 x 5 Xelox (5m) (8w) TME
• End point : 3y DFS
• Stat : 3y DFS : 50% 60%
880 pts (SW - NL - It …)
Dutch M1 : 5 x 5 – Xelox – BVZ : 50pts : 26% pCR
R
76
Trial : Local ontrol – Phase III - 2014
• GRECCAR 4 : T3c-T4 MRI (Ph Rouanet)
Folfirinox 4 cycles – Response MRI (CRM)
Poor CAP 50 – TME
Response CAP 60 – TME
AIM : reduce R0 rate – increase cCR and AR
R
ACCORD 12 – Phase III
T3-T4 M0 : Cap 50 (Capecitabine + 50 Gy)
Age < 70y (442) Age ≥ 70y (142)
PS 0-1 99.8% 99.2%
RXT-stop 1.4% 4.2% 0.03
Surgery 99 % 95 % 0.008
Stoma 23 % 33 % 0.01
Death 6 months 6 % 12 % n.s.
Gérard JCO 2012 François Rad Onc 2014
78
Prodige T3-4 TOXICITY ≥ 75 years (2015)
• Aim : reduce toxicity – increase surgery
CAP50 + TME
25 Gy/5 + TME
• End point : - surgery performed
- 2 y DFS –Toxicity- Q o Life
R
79
the Complete
Response
Revolution
Clinical Complete Response : cCR
for ORGAN PRESERVATION
FICARE
Sao Paulo
Nov 2013
W Heald
80
« upcoming » GRECCAR 12
Goal : Increase Loc Excision : organ preservation
Inclusion : T2-3 < 4cm Distal- middle Rectum
Cap50 - W 12 : LE or TME
Folfirinox (4)- CAP 50 : LE or TME
Loc Excision if T ≤ 2cm if pT2-3 : TME
End point : Organ preservation at 1 year
Hypothesis : 40 % vs 60 %
R
/2009/2009
T 2-3a-b < 5 cm N0-1 M0 Operable ; low-mid rectum
RCRT + EBRT : 9 Gy
CRT + Cont X B :90 Gy
OPERA : Phase III 0rgan Preservation Early Rectal Adenocarcinoma
W 14
End point : organ (rectal) preservation 3 years
Hypothesis : 20 % to 40 % : 236 pts (dec 2019?)
Clinical
response
Resp
Partial : TME
cCR : Watch/ Wait or Loc Excision
Rectal adenocarcinoma T2 T3 a-b
OPERA randomized trial
4- 2014 M 69y MRI :T3a N0
90 Gy/3f CXB+ CAP 50
cCR 8-2014 - Loc Exc
ypT0
D1
D28
84
OPERA – Europe : promotion CAL Nice• UK : 4 ( 7 )
•France : 3 ( 4 ) Nice - Lyon villeurb - Mâcon
•DK : 2
Sweden : 1 Suisse : 1 ?
Start : February 2015 (CPP-ANSM- PHRC)
10 units (32) : 80 patients / year (60 -80-100)
Results December 2019 : Organ preseerved 40% T2-3ab
85
1971
Clinical Approach
Tumor Evaluation ++
Before treat t - During + - After
Clinical Tumor Response
cCR - Local Control (loc rec)
DRE - Rectoscopy - Imaging
86
Gina Brown
performing Proctoscopy
Back to the CLINIC !
87
ROENTGEN
26 décembre 1895 DESPEIGNES 1896
Observation
concernant un cas de
cancer de l’estomac
traité par les rayons
Roentgen
par le Docteur Victor
Despeignes,
Lyon Médical
July 1896: 428
1902 1912
STOCKHOLM